# ResMed

Type: Company (RMD)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/resmed
Canonical HTML page: https://getfinancebrief.com/entity/resmed

## Recent coverage (2 stories)

### ASX 200 Eyes 12% Earnings Surge, First Growth in Years
2026-08-01 22:39:50 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Australian companies are forecast to deliver 12% aggregate profit growth this earnings season, breaking a three-year decline. Key risks loom from energy costs, wage inflation, and rising bad debts, particularly for banks like CBA and Westpac.
Full story: https://getfinancebrief.com/story/asx-200-earnings-season-12-percent-growth

### ResMed Targets Drop to $225 at Wells Fargo; Upside Remains at +23.2%
2026-07-10 14:15:12 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside. Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
Full story: https://getfinancebrief.com/story/resmed-stock-analyst-target-cuts-wells-fargo

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.